Introduction
The rare entity of "oncogenic osteomalacia" also known as "tumour induced osteomalacia", is a paraneoplastic condition that is characterized by the development of muscle weakness, bone pains, fractures and deformities secondary to tumours secreting phosphotonins in turn causing phosphaturia and hence hypophosphatemia. Early description of the disease dates back to 1959, when it was first described as the occurrence of severe and progressive rachitic changes in an 11 1 / 2 year old girl. Further evaluation of the same had shown the presence of renal phosphate wasting in the presence of a normal renal function and a giant cell tumour in the rib. Upon removal of the tumour, there was healing of rickets. 1 The clinical features of oncogenic osteomalacia are attributed to hypophosphatemia secondary to renal phosphate wasting usually caused by a phosphaturic factor, known as phosphatonins which have subsequently been identified as fibroblast growth factor À23 (FGF-23). 2 Other phosphatonins which have been identified to cause hypophosphatemic osteomalacia are secreted frizzled related protein-4 (sFRP-4), matrix extracellular phosphoglycoprotein and FGF-7. 3 Biochemically, oncogenic osteomalacia is characterized by hypophosphatemia, inappropriately low 1, 25 OH vitamin D and elevation in the levels of FGF-23. 2 The condition rather has a dramatic presentation, and upon removal of the tumour, there is remarkable improvement in the symptomatology. The prototype of the tumours responsible is the phosphaturic mesenchymal tumours, mixed connective tissue variant (PMTMCT). Identification of these tumours is often difficult, as they are usually slow growing and indolent. Functional imaging like somatostatin based scintigraphy has recently been shown to be helpful in the detection of these small tumours that express somatostatin receptors. 4 Surgical excision of these tumours usually results in clinical recovery following a decline in the levels of FGF-23. 5 These mesenchymal tumours may occur anywhere in the body and have been reported from the extremities, head and neck region as well as from other musculoskeletal parts of the body. The tumours from musculoskeletal region form an important subgroup of oncogenic osteomalacia in terms of requiring detailed whole body imaging for the localization of these tumours. We report our experience in the clinical features, detection, management and clinical outcomes of tumour induced osteomalacia, in the musculoskeletal region.
Materials and methods

Patients
It was a retrospective study conducted at the department of Endocrinology, tertiary care centre in southern India. We analysed the hospital records of all the patients with a diagnosis of adult onset hypophosphatemic osteomalacia from Centralised Hospital Information Processing Services (CHIPS) without any significant family history from January 2010 to April 2016. All the patients who were diagnosed to have hypophosphatemic osteomalacia secondary to tumours of musculoskeletal region were recruited into the study. The clinical, biochemical and radiological data of 13 patients of musculoskeletal oncogenic osteomalacia were analysed. This study was approved by institutional review board.
Methods
A detailed medical history including family history and physical examination findings of patients with adult onset hypophosphatemic osteomalacia were taken into consideration for the study. Baseline fasting serum calcium (N: 8.3-10.4 mg/dL), phosphate (N: 2.5-4.6 mg/dL), alkaline phosphatase (ALP){N: 40-125U/L}, tubular maximum of phosphate/Glomerular filtration rate (TMP/GFR) (N: !2.5), 25 OH vitamin D (N: 30-75 ng/ml), PTH (N: 8-74 pg/ml) and Fibroblast growth factor (FGF 23)(N: 22-91RU/ml) levels were obtained. Tubular maximum of phosphate/glomerular filtration rate (TMP/GFR) was calculated from the nomogram of Walton and Bijvoet. 6 Details regarding functional imaging (isotope scan) {FDG PET/CT or DOTATE PET/CT} or whole body Tc 99 m Red blood cell (RBC) blood pool scintigraphy were obtained. Following localization and surgical excision of the tumour, the biopsy specimens confirmed the presence of mesenchymal phosphaturic tumour. Serum calcium, phosphate, ALP and FGF 23 levels were measured in the post-operative period and during follow up for assessing the remission status.
Results
Of seventy three patients who presented with adult onset hypophosphatemic osteomalacia, 13 subjects (M:F = 6:7) were diagnosed to have musculoskeletal oncogenic osteomalacia with a mean age of 45.3 AE 18.2 years ( Table 1) .
The mean duration of symptoms prior to initial hospital visit was 51.1 AE 63.1 months (Tables 1 and 2) . Mean FGF 23 level was 828.86 AE 113.22 RU/ml. All patients had functional imaging for localization [3 patients -FDG PET/CT, 8 patients-DOTATATE PET/ CT and 1 patient-both modalities of imaging and whole body Tc-99 m Red blood cell (RBC) blood pool scintigraphy in 2 patients]. Nine patients underwent surgical excision of the tumour following localization, and 4 patients declined consent for surgery (Table 3 ). Fig. 1 shows an increased uptake in the lesion on DOTATATE PET/CT done in one of the patients (patient no. 3). All the biopsy specimens of 9 patients who underwent surgery showed the presence of phosphaturic mesenchymal tumour {Fig. 2, patient no.4} (6 had mesenchymal tumours, 2 had mixed connective tissue variant and 1 had a variant of non ossifying fibroma). All except one were in remission after the first surgery (patient no. 3 required second surgery in view of not attaining remission after first surgery). The post operative FGF-23 levels versus preoperative FGF-23 levels in patients who underwent surgery showed significant reduction (P < 0.05) ( Table 3 ).
Discussion
Oncogenic osteomalacia was seen in 31.5% of adult patients with hypophosphatemic osteomalacia out of which 56.5% were from the musculoskeletal region. Most prominent symptoms seen in our patients with musculoskeletal oncogenic osteomalacia were bony pains (77%), proximal muscle weakness (61.5%) and fractures (30%) ( Table 2 ) which is concurrent with the available literature. 7 The nuclear scintigraphy imaging enabled to localise lesions in most of our patients, thus underlying the importance of functional imaging in the diagnosis of these rare tumours. The commonest location of the tumour in our series was in the lower extremities and was seen in about 85% of patients; majority of them had bony lesions (Table 3) . These findings correlate with what has been observed in another study. 7 All the patients who underwent surgery were in remission. The commonest histological subtype seen in our patients with musculoskeletal oncogenic osteomalacia was phosphaturic mesenchymal tumour/mixed connective tissue tumour. Most of these tumours are benign with low nuclear grade and poor mitotic activity. 2 Oncogenic osteomalacia also known as "tumour induced osteomalacia", is a rare paraneoplastic syndrome usually caused by small endocrine tumours that secrete several phosphaturic hormones like fibroblast growth factor (FGF-23) leading to hypophosphatemia. 2, 8, 9 Oncogenic osteomalacia is one of the remediable causes of hypophosphatemic osteomalacia since the resection of the tumour leads to cure of this condition. 10 This is a rare condition and less than 500 cases have been reported from across the world. 2, 7 They usually present with proximal muscle weakness, bony pains or pathological fractures. The commonest sites of the tumour in decreasing order were thigh and femur, head and neck, ankle and foot, pelvis, tibia and fibula followed by arms. Thus musculoskeletal group forms a major subcategory among the oncogenic osteomalacia. One of the most challenging aspects of oncogenic osteomalcia is to localise the tumour. Since these phosphaturic tumours are very small, various imaging techniques have been used like whole body Tc 99 m Red blood cell (RBC) blood pool scintigraphy,computed tomography (CT), whole body magentic resonance imaging (MRI), Fluorodeoxyglucose (18FFDG) positron emission tomography (PET/CT) or Gallium (68Ga) DOTATATE PET/CT. 4, [11] [12] [13] The most common histological picture is phosphaturic mesenchymal tumour (PMT) with the subtypes: PMT mixed conective tissue tumour (commonest), nonossifying fibroma-like, ossifying fibroma-like and osteoblastoma-like PMT. The other histological types of oncogenic osteomalacia reported are giant cell tumour, hemangioma, hemangiopericytoma and osteosarcoma. 14, 7 Identifying the precise location of these tumours is important as surgical excision leads to remission. The treatment of this condition in the perioperative period include phosphate and active vitamin D3 supplementation. Although surgical excision is the treatment of choice, in selected cases where surgery is not feasible, other modalities of treatment with somatostatin analogues, chemotherapeutic agents like cisplatin and doxorubicin and external beam radiotherapy may be empolyed. 2 In conclusion, oncogenic osteomalacia is an important treatable cause for hypophosphatemic osteomalacia where surgery plays a pivotal role and excision of the tumour leads to cure of the disease. Tumours originating from the musculoskeletalregion is an important subcategory of oncogenic osteomalacia and needs more elaborate imaging modalities for precise localization and subsequent treatment.
